Indications and main treatment areas of pirfenidone tablets

Pirfenidone is an oral small-molecule anti-fibrosis drug currently widely recommended by international authoritative guidelines for the treatment of idiopathic pulmonary fibrosis (IPF). Its mechanism of action is mainly by inhibiting inflammatory pathways such as transforming growth factor-β (TGF-β) and tumor necrosis factor (TNF-α), reducing collagen deposition and fibrosis progression in the lungs, thereby delaying the decline of lung function. Currently, pirfenidone's approved indications in many countries around the world are mainly IPF, which is an interstitial lung disease with unknown cause, strong progression, and poor prognosis. Patients often develop severe respiratory failure within 2-5 years after onset, so early intervention is particularly critical.

Pirfenidone can significantly slow down the decline of vital capacity (FVC), reduce the incidence of acute exacerbations, and prolong disease progression-free survival to a certain extent. In addition to IPF, in recent years, overseas countries have also begun to explore the application potential of pirfenidone in other types of pulmonary fibrosis, such as connective tissue disease-associated pulmonary fibrosis (CTD-ILD), chronic hypersensitivity pneumonitis (CHP), and non-specific interstitial pneumonia (NSIP). In China, the official indications of this drug are still mainly IPF, but some medical institutions have tried to use it "off-label" in other fibrotic lesions in clinical practice, which needs to be combined with individualized evaluation.

It is worth noting that pirfenidone is not a hormonal drug, so its safety and long-term tolerance are better than traditional immunosuppressants, especially for patients who cannot tolerate hormonal therapy. During medication, liver function should be monitored regularly, contact with strong ultraviolet rays should be avoided, and adverse reactions such as photosensitivity reactions and gastrointestinal discomfort should be assessed. With the increase in the recognition rate of pulmonary fibrosis in China and the advancement of drug combination treatment options, pirfenidone has increasingly broad prospects for use in the field of pulmonary fibrosis, and is expected to bring new treatment hope to more patients with fibrotic lesions.

Reference materials:https://www.esbriet.com/